

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM S-8  
REGISTRATION STATEMENT**  
*UNDER  
THE SECURITIES ACT OF 1933*

---

**Aurinia Pharmaceuticals Inc.**

*(Exact name of registrant as specified in its charter)*

**Alberta, Canada**  
(State or other jurisdiction of incorporation or organization)

**98-1231763**  
(IRS Employer Identification No.)

**#140, 14315 - 118 Avenue  
Edmonton, Alberta  
T5L 4S6**  
(Address of principal executive offices) (Zip code)

**Aurinia Pharmaceuticals Inc. Amended and Restated Equity Incentive Plan**  
(Full title of the plan)

---

**Stephen Robertson  
Executive Vice President, General Counsel,  
Chief Compliance Officer and Corporate Secretary  
Aurinia Pharmaceuticals Inc.  
#140, 14315 - 118 Avenue  
Edmonton, Alberta  
T5L 4S6  
(Name and address of agent for service)  
(250) 744-2487  
(Telephone number, including area code, of agent for service)**

*Copies to:*

**Raquel Fox  
Skadden, Arps, Slate, Meagher & Flom LLP  
1440 New York Avenue, NW  
Washington, DC 20005  
(202) 371-7000**

**Michelle Wilkinson  
Borden Ladner Gervais LLP  
1200 Waterfront Centre  
P.O. Box 48600  
Vancouver, British Columbia V7X 1T2  
(604) 687-5744**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐  
Non-accelerated filer ☐ Smaller reporting company ☐  
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

---

## EXPLANATORY NOTE

### **Aurinia Pharmaceuticals Inc. Amended and Restated Equity Incentive Plan**

This Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 6,000,000 common shares, no par value per share (the “Common Shares”) of Aurinia Pharmaceuticals Inc. (the “Registrant”), in connection with the Aurinia Pharmaceuticals Inc. Amended and Restated Equity Incentive Plan.

## PART I

### INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

#### **Item 1. Plan Information.\***

#### **Item 2. Registrant Information and Employee Plan Annual Information.\***

\* The documents containing the information specified in “Item 1. Plan Information” and “Item 2. Registrant Information and Employee Plan Annual Information” of Form S-8 will be sent or given to participants in the Plans, as applicable, as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be, and are not, filed with the Commission either as part of this Registration Statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

---

## PART II

### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Certain Documents by Reference.

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement as of their respective dates:

1. the Registrant's Annual Report on [Form 10-K](#) for the year ended December 31, 2024, as filed with the Commission on February 27, 2025;
2. the Registrant's Quarterly Report on [Form 10-Q](#) for the quarterly period ended March 31, 2025, filed with the Commission on May 12, 2025;
3. the Registrant's Current Report on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed with the Commission on [May 15, 2025](#); and
4. the description of the Common Shares contained in [Exhibit 4.3](#) to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Commission on February 24, 2021, including any future amendment or report filed for the purpose of amending such description.

In addition, all reports and documents filed by the Registrant under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities being offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in and to be part of this Registration Statement from the date of filing of each such document, provided that reports on Form 8-K shall be so deemed incorporated by reference only if and to the extent indicated in such reports.

Unless expressly incorporated into this Registration Statement, a report furnished but not filed on Form 8-K under the Exchange Act shall not be incorporated by reference in to this Registration Statement.

#### Item 4. Description of Securities.

Not applicable.

#### Item 5. Interests of Named Experts and Counsel.

Not applicable.

#### Item 6. Indemnification of Directors and Officers.

Under the *Business Corporations Act* (Alberta) (the "ABCA"), except in respect of an action by or on behalf of the Registrant or a Related Entity (as defined below) to procure a judgement in its favor, the Registrant may indemnify a present or former director or officer of the Registrant or a person who acts or acted at the Registrant's request as a director or officer of another entity of which the Registrant is or was a shareholder or creditor ("Related Entity"), and the director's or officer's heirs and legal representatives against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the director or officer in respect of any civil, criminal, administrative, investigative or other action or proceeding (a "Proceeding") in which the director or officer is involved by reason of being or having been a director or officer of the Registrant or Related Entity and provided that (i) such person acted honestly and in good faith with a view to the best interests of the Registrant and Related Entity, as applicable, and (ii) in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, had reasonable grounds for believing that such person's conduct was lawful. The indemnification may be made in connection with a derivative action only with court approval.

Any of the persons described in the first sentence of the foregoing paragraph are entitled to indemnification from the Registrant as a matter of right if the person seeking indemnity (a) was not judged by a court or competent authority to have committed any fault or omitted to do anything that the person ought to have done, and (b) fulfilled the conditions set forth in (i) and (ii) above.

---

The Registrant may advance monies to any person described above for the costs, charges and expenses of a Proceeding. However, the person must repay the monies if the person does not fulfill the conditions set forth above.

The foregoing description is qualified in its entirety by reference to the ABCA.

The Registrant is a party to an indemnity agreement with each director and officer of the Registrant providing that if such director or officer is or was involved in any threatened, pending or completed Proceeding by reason of the fact that such director or officer is or was a director or officer of the Registrant or is or was serving at the request of the Registrant as a director or officer of another entity, including service with respect to employee benefit plans, whether the basis of such Proceeding is an alleged action in an official capacity while serving as a director or officer, such director or officer will be indemnified and held harmless by the Registrant to the fullest extent authorized by and in the manner set forth in the ABCA against all expense, liability and loss reasonably incurred or suffered by such director or officer in connection therewith. Under such indemnity agreements, the Registrant may indemnify any of its directors or officers in connection with a Proceeding (or part thereof) initiated by such director or officer only if such Proceeding (or part thereof) is authorized by the board of directors of the Registrant or if such Proceeding is a successful Proceeding, in whole or in part, by a director or officer for claims under an indemnity agreement.

The ABCA provides that the Registrant may purchase and maintain insurance for the benefit of any persons described in the first sentence of the first paragraph of this section against any liability incurred by the person in the person's capacity as a director or officer of the Registrant or Related Entity.

The Registrant maintains directors' and officers' liability insurance. The policies insure (a) the directors and officers of the Registrant against losses arising from claims against them for certain of their actual or alleged wrongful acts (as defined within the insurance policy), (b) the Registrant for payments made pursuant to the Registrant's indemnification of its directors and officers and (c) the Registrant when it is directly named in a securities claim. The policies provide a maximum coverage in any one policy year of \$60 million in annual claims, \$25 million of which is dedicated solely to the directors and officers of the Registrant for non-indemnifiable claims. A \$3.5 million per claim deductible is applicable to indemnifiable claims and securities claims brought against the Registrant; no deductible shall apply to non-indemnifiable claims. The premiums for the policies were not allocated between directors and officers as separate groups.

By-law No. 2 of the Registrant provides that, except as otherwise provided in the ABCA, no director or officer will be liable for:

- a) the acts, receipts, neglects or defaults of any other director, officer or employee, or for joining in a receipt or act for conformity;
- b) any loss, damage or expense happening to the Registrant through the insufficiency or deficiency of title to any property acquired by, for, or on behalf of the Registrant;
- c) the insufficiency or deficiency of any security in or upon which monies of or belonging to the Registrant shall be placed or invested;
- d) any loss or damage arising from the bankruptcy, insolvency or tortious acts of any person, firm or corporation, including any person, firm or corporation with whom any monies, securities or other effects of the Registrant is lodged or deposited;
- e) any loss, conversion, misapplication or misappropriation of or any damage resulting from any dealings with any monies, securities or other assets of or belonging to the Registrant; or
- f) any other loss, damage, or misfortune which may happen in the execution of the duties of a director's or officer's respective office or trust or in relation thereto;

unless the foregoing shall happen by or through such director's or officer's failure to exercise the powers and to discharge the duties of their office honestly and in good faith with a view to the best interests of the Registrant and through a failure to exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

---

**Item 8. Exhibits.**

Exhibit Number	Description	Incorporated by Reference			
		Form	File Number	Exhibit	File Date
4.1	<a href="#">Articles of Amalgamation of Aurinia Pharmaceuticals Inc., as amended, as currently in effect.</a>	10-K	001-36421	3.1	February 24, 2021
4.2	<a href="#">Amended and Restated By-Law No. 2, as amended and currently in effect</a>	8-K	001-36421	3.1	May 15, 2025
4.3	<a href="#">Form of Common Shares Certificate of Aurinia Pharmaceuticals Inc.</a>	10-K	001-36421	4.1	February 24, 2021
5.1*	<a href="#">Opinion of Borden Ladner Gervais LLP</a>				
10.1	<a href="#">Aurinia Pharmaceuticals Inc. Equity Incentive Plan, as amended and restated as of May 15, 2025</a>	8-K	001-36421	99.1	May 15, 2025
23.1*	<a href="#">Consent of Borden Ladner Gervais LLP (included in Exhibit 5.1)</a>				
23.2*	<a href="#">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</a>				
24.1*	<a href="#">Power of Attorney (included on the signature page of this Form S-8).</a>				
107*	<a href="#">Filing Fee Table</a>				

---

\* Filed herewith

**Item 9. Undertakings.**

(a) The undersigned Registrant hereby undertakes,

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement;

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in this Registration Statement;

*provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Rockville, State of Maryland, on May 16, 2025.

### **AURINIA PHARMACEUTICALS INC.**

By: /s/ Peter S. Greenleaf  
Peter S. Greenleaf  
President and Chief Executive Officer

---

## POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Peter S. Greenleaf and Joseph M. Miller, and each of them, any of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this Registration Statement and registration statements filed pursuant to Rule 429 under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, each acting alone, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

Signature	Title	Date
<hr/> /s/ Peter S. Greenleaf Peter S. Greenleaf	President, Chief Executive Officer <i>(Principal Executive Officer)</i>	May 16, 2025
<hr/> /s/ Joseph M. Miller Joseph M. Miller	Chief Financial Officer <i>(Principal Financial Officer and Principal Accounting Officer)</i>	May 16, 2025
<hr/> /s/ Kevin Tang Kevin Tang	Chair of the Board	May 16, 2025
<hr/> /s/ Jeffrey A. Bailey Jeffrey A. Bailey	Director	May 16, 2025
<hr/> /s/ Kathy L. Goetz Kathy L. Goetz	Director	May 16, 2025
<hr/> /s/ Craig Johnson Craig Johnson	Director	May 16, 2025
<hr/> /s/ Tina S. Nova Tina S. Nova	Director	May 16, 2025



# Calculation of Filing Fee Tables

## S-8

### Aurinia Pharmaceuticals Inc.

Table 1: Newly Registered Securities

	Security Type	Security Class Title	Fee Calculation Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
1	Equity	Common shares no par value	457(a)	6,000,000	\$ 7.72	\$ 46,320,000.00	0.0001531	\$ 7,091.59
Total Offering Amounts:						\$ 46,320,000.00		\$ 7,091.59
Total Fee Offsets:								\$ 0.00
Net Fee Due:								\$ 7,091.59

#### Offering Note

1

Amount Registered: Represents common shares, no par value (the "Common Shares"), of Aurinia Pharmaceuticals Inc. (the "Registrant") that may be offered or issued under the plans set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of Common Shares of the Registrant.

Proposed Maximum Offering Price per Unit: Estimated in accordance with Rule 457(c) and Rule 457(h) under the Securities Act of 1933, as amended, (the "Securities Act") solely for the purpose of calculating the registration fee on the basis of \$7.72, the average of the high and low price of the Common Shares as reported on the Nasdaq Global Market on May 14, 2025.

---

Borden Ladner Gervais LLP  
 1200 Waterfront Centre  
 200 Burrard St, P.O. Box 48600  
 Vancouver, BC, Canada V7X 1T2  
 T 604.687.5744  
 F 604.687.1415  
 blg.com



May 16, 2025

Aurinia Pharmaceuticals Inc.  
 #140, 14315 – 118 Avenue  
 Edmonton, AB T5L 4S6

Dear Sirs/Mesdames:

**RE: AURINIA PHARMACEUTICALS INC.**

We are acting as Canadian counsel to Aurinia Pharmaceuticals Inc. (the "**Corporation**") in connection with the filing on the date hereof of a Registration Statement on Form S-8 (the "**Form S-8**") registering an additional 6,000,000 common shares of the Corporation (the "**Shares**") issuable in accordance with the Corporation's Amended and Restated Equity Incentive Plan (the "**Plan**"). We have made such investigations and examined originals or copies certified or otherwise identified to our satisfaction of such documents, records and certificates of the Corporation as we have considered necessary or relevant for the purposes of this opinion including:

- (a) the restated articles and by-laws of the Corporation, each as amended to date;
- (b) the Plan; and
- (c) resolutions of the directors and shareholders of the Corporation authorizing the Plan, including any amendments or supplements thereto.

For purposes of this opinion, we have assumed with respect to all documents examined by us, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to authentic original documents of all documents submitted to us as certified, conformed, telecopied or photostatic copies and the legal capacity of all individuals who have executed any of such documents. We have assumed: (i) that copies of all documents submitted to us have been executed in the form reviewed by us, have not been amended or modified, since the date they were submitted to us, by written or oral agreement of the parties thereto, by the conduct of the parties thereto, or otherwise; (ii) that all representations and certificates dated prior to or on the date hereof upon which we have relied continue to remain accurate in all material respects as of the date hereof; and (iii) that the aforesaid copies have been executed and unconditionally delivered by the Corporation in the form reviewed by us.

Based and relying upon and subject to the foregoing we are of the opinion that the Shares, when issued and paid for in accordance with the Plan will be validly issued as fully paid and non-assessable shares in the capital of the Corporation.

The foregoing opinion is limited to the laws of Alberta and the federal laws of Canada applicable therein.

We consent to the filing of this opinion as an exhibit to the Form S-8. In giving such consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of the United

Borden Ladner Gervais LLP  
1200 Waterfront Centre  
200 Burrard St, P.O. Box 48600  
Vancouver, BC, Canada V7X 1T2  
T 604.687.5744  
F 604.687.1415  
blg.com



States Securities Act of 1933 or the rules and regulations of the Securities and Exchange Commission  
thereunder.

Yours very truly,

*(signed) "Borden Ladner Gervais LLP"*

**Consent of Independent Registered Public Accounting Firm**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Aurinia Pharmaceuticals Inc. (the Registrant) of our report dated February 26, 2025 relating to the consolidated financial statements and effectiveness of internal control over financial reporting of the Registrant, which appears in the Registrant's Annual Report on Form 10-K for the year ended December 31, 2024.

/s/PricewaterhouseCoopers LLP

**Chartered Professional Accountants, Licensed Public Accountants**  
Toronto, Canada

May 16, 2025